COVID-19 Antibody Test (IgG): What It Shows, What It Cannot Tell You, and How It Differs from RT-PCR and TrueNat

Key takeaways

• Different question: The IgG antibody test asks "has this immune system met the virus or the vaccine before?", not "am I infected today?"
• Not a diagnostic test for acute illness: IgG usually becomes detectable days to weeks after symptom onset, so a negative result early in illness means little.
• Not an immunity certificate: No antibody level is validated as a threshold for protection against infection or severe disease. Results should not change masking, isolation or vaccination decisions.
• Assays are not interchangeable: Spike-based and nucleocapsid-based tests answer different questions, and numeric values from different laboratories cannot be compared.
• RT-PCR and TrueNat detect the virus itself from a nose or throat swab; the antibody test detects the body's response and cannot replace them.

At a glance

Results vary depending on individual clinical circumstances.

Also known as

• COVID antibody test, COVID-19 serology test
• SARS-CoV-2 IgG, anti-SARS-CoV-2 IgG
• Anti-spike IgG / anti-S IgG; anti-nucleocapsid IgG / anti-N IgG
• CLIA or ECLIA COVID antibody test (chemiluminescence-based laboratory assays)
• COVID ELISA test
• Commonly asked for in India as "COVID blood test", "antibody wala test", or "immunity test", the last term is misleading and is corrected below

What the COVID-19 IgG antibody test is

Antibodies are proteins made by the immune system that bind to parts of a virus. After SARS-CoV-2 infection or vaccination, the body makes several classes of antibody. IgM tends to appear earlier and fade; IgG appears somewhat later and persists for longer, though for how long varies widely between individuals.

The IgG antibody test is performed on blood, not on a nose or throat swab. Laboratory platforms include ELISA and automated chemiluminescence assays (CLIA/ECLIA); rapid lateral-flow cassettes also exist and are generally less reliable than laboratory platforms.

An important practical point: the target protein matters.

• Anti-spike (anti-S) IgG may be positive after infection or after most COVID-19 vaccines, so a positive result cannot separate the two.
• Anti-nucleocapsid (anti-N) IgG is generally not produced by spike-based vaccines, so it is used in research to suggest past natural infection. Inactivated whole-virus vaccines, however, can also generate anti-N responses.

Your report should state which antigen was used. If it does not, the result is hard to interpret.

Why the COVID-19 IgG antibody test is done

• Evidence of past exposure when someone had an untested illness weeks or months earlier and a doctor needs supporting information.
• Assessment of vaccine or infection response in selected patients, such as some people with immune suppression, where a specialist is weighing further preventive measures.
• Investigation of post-infectious conditions where serological evidence of prior SARS-CoV-2 infection forms part of a wider assessment, including suspected multisystem inflammatory syndrome in children (interpreted only by the treating paediatric team).
• Public health seroprevalence surveys to estimate what proportion of a population has been exposed.
• Plasma or blood donor programmes, where antibody screening may be part of the protocol.

Who should get this test

The COVID-19 IgG antibody test is a selective test, not a general health check. It may be reasonable when:

• A doctor is looking for evidence of past infection weeks to months after an illness that was never tested.
• A specialist is assessing immune response in a person on immunosuppressive therapy, after organ transplantation, or with a known immunodeficiency, as part of a wider plan.
• A treating team is investigating a post-COVID or post-infectious inflammatory illness.
• A person is participating in a research study, seroprevalence survey or donor programme.

Who should not rely on this test: anyone with current fever, cough, sore throat, loss of smell or breathlessness. Those symptoms need a test that detects the virus, RT-PCR, TrueNat or rapid antigen, not an antibody test. The IgG test is also not a valid test for deciding whether you can skip a vaccine dose, stop precautions, travel, return to work, or "check immunity".

What the COVID-19 IgG antibody test cannot detect or exclude

• It cannot diagnose current infection. A person can be infectious and shedding virus while IgG is still undetectable.
• It cannot exclude past infection. Some people, particularly those with mild or asymptomatic infection or with immune suppression, mount little detectable IgG; antibody levels also fall over time. A non-reactive result means antibodies were not identified by that assay on that day, it does not prove the infection never happened.
• It cannot measure immunity or protection. There is no validated antibody threshold that guarantees protection. Cellular (T-cell) and memory B-cell immunity are not measured by this test at all.
• It cannot tell you when the infection occurred, or which variant was involved.
• It cannot separate infection from vaccination if a spike-based assay is used.
• Neutralising ability is not assessed. Standard IgG assays are binding assays; they do not show whether antibodies can neutralise the virus.
• Numbers are not comparable across laboratories. A value of, say, 50 units on one platform has no fixed relationship to 50 units on another.

If symptoms persist or worsen despite a normal or non-reactive result, go back to your doctor rather than treating the result as reassurance.

Related but different examinations

These tests are often bundled together in conversation, but they answer different questions. None is universally superior; the right test depends on the clinical problem.

Which comes first? With current respiratory symptoms or a recent exposure, a virus-detection test (RT-PCR, TrueNat or antigen) comes first. For a question about an illness that happened weeks or months ago, serology is the only one of these that can help. For assessing vaccine response in immunosuppression, an anti-spike IgG test is the relevant choice, but only within a specialist plan.

How to prepare

Preparation is short and largely operational. Instructions differ between laboratories, and your collection centre's written instructions take precedence over anything you read here.

• Fasting is generally not required for SARS-CoV-2 IgG testing. If the sample is being drawn alongside a lipid profile or glucose test, the fasting rule for those tests applies.
• Take your usual medicines as prescribed. Do not start, stop or alter any prescribed medicine for this test, speak to the prescriber if you have a concern.
• Tell the laboratory if you have received COVID-19 vaccination, a booster, or plasma or immunoglobulin therapy, and when. This information changes how the result is read.
• Mention any bleeding disorder or blood-thinning medication so the staff can apply pressure for longer.
• Drink water normally unless you are under a medical fluid restriction.
• Carry your prescription, ID and any previous COVID test or vaccination records.

If you have current COVID-like symptoms

Do not walk into a collection centre unannounced. Telephone first, wear a mask, and ask what pathway is in place. A symptomatic person needs a virus-detection test, not an antibody test.

Children

Paediatric blood sampling uses smaller volumes and paediatric-trained staff; not every centre offers this. Reference behaviour of antibody tests in children is less well characterised, and interpretation belongs to the treating paediatrician.

Pregnancy

A venous blood draw carries no special pregnancy-related concern. Interpretation, including after vaccination in pregnancy, should be discussed with the obstetric team.

Older adults and people on anticoagulants

Bruising at the puncture site is more likely. Pressure over the site for several minutes reduces it.

People with immune suppression or on immunoglobulin therapy

Antibody results in this group can be falsely reassuring or falsely negative, and recent immunoglobulin or plasma products can introduce antibodies that are not your own. These tests should only be ordered and interpreted by the treating specialist.

What happens during the test and how long the process takes

• Registration and consent: a few minutes.
• Blood collection: a tourniquet is applied, the skin cleaned, and 2-5 mL of blood drawn from an arm vein. The needle is in place for well under a minute. Fingerprick kits take less time but are generally less reliable.
• After collection: pressure is applied, the site dressed, and you can usually leave immediately. Total visit time is commonly 10-20 minutes, depending on the queue.
• Laboratory processing: automated CLIA/ECLIA platforms run a sample in well under an hour once loaded; ELISA plates take longer. Rapid cassette kits show a line within about 15-30 minutes.

Reporting time depends on the laboratory's batching, courier schedules and whether the sample is tested in-house or referred. Ask your unit when your report will be ready, as this is unit-specific.

Understanding your report

The COVID-19 IgG report will usually read as reactive/positive, non-reactive/negative, or occasionally equivocal or borderline. Many laboratories also give a number, an index, ratio, AU/mL or BAU/mL, with a cut-off set by the manufacturer for that specific assay.

• Reactive / positive: IgG antibodies against the tested antigen were detected. This is consistent with past infection, past vaccination, or both. It does not tell you when, and it does not tell you that you are protected.
• Non-reactive / negative: antibodies were not detected by this assay. Possible reasons include no prior exposure, testing too early, a weak antibody response, waning antibodies, or immune suppression.
• Equivocal / borderline: the value sits close to the cut-off. Your doctor may repeat the test later or simply not act on it.

About the numbers: a higher number is not a licence to relax precautions, and a lower number is not proof of vulnerability. Values from different laboratories or different platforms cannot be compared, so a "drop" between two reports from different labs may be a difference in assay, not in you. No number on this report should be read as a protection score. Interpretation always belongs to the doctor who requested the test, in the context of your symptoms, vaccination history and treatment.

When results can be misleading

Falsely raised or falsely positive results

• Cross-reactivity with antibodies to other coronaviruses or with certain autoantibodies, particularly with less specific rapid kits.
• Recent plasma, immunoglobulin or monoclonal antibody therapy introducing antibodies that did not come from your own immune system.
• Rheumatoid factor and heterophile antibodies, a recognised source of interference in immunoassays.
• Misreading a vaccine response as infection when a spike-based assay is used.
• Testing in a low-prevalence setting, where even a good assay produces a higher proportion of false positives among all positives.

Falsely lowered or falsely negative results

• Testing too early: IgG usually takes days to weeks after symptom onset to become detectable.
• Waning antibodies months after infection or vaccination.
• Mild or asymptomatic infection, which often produces weaker responses.
• Immunosuppressive therapy, B-cell depleting drugs such as rituximab, haematological cancers and primary immunodeficiency.
• Antigen mismatch: an anti-N assay will be non-reactive after a spike-only vaccine even though the vaccine worked.
• Haemolysed, lipaemic or improperly stored samples, which may be rejected or give unreliable values.

Risks and safety

Venous blood sampling

Venepuncture is a low-risk procedure. Expected effects include brief pain and a small bruise. Less common problems include lightheadedness or fainting, a larger haematoma (more likely on blood thinners), and, rarely, local infection or temporary nerve irritation.

Fingerprick rapid kits

Discomfort at the fingertip and a small bruise are usual. The main risk here is not physical but interpretive: rapid cassettes vary considerably in performance, and a home or roadside result can mislead if acted on without medical advice.

Risk of acting on the result

The most important harm associated with COVID-19 antibody testing is behavioural, treating a reactive result as proof of immunity and dropping precautions or skipping recommended vaccination. Discuss vaccination decisions with your doctor, not with a test report.

Results vary depending on individual clinical circumstances.

Special situations

Pregnancy

Antibody testing in pregnancy is not routine. Vaccination decisions in pregnancy are guided by obstetric advice and national recommendations, not by an antibody level. A maternal antibody result does not predict newborn protection in any measurable way.

Children

IgG serology in children is mainly used within a clinical assessment, such as suspected post-infectious inflammatory syndrome, and by paediatric teams. Antibody testing is not a way to decide whether a child can attend school or skip precautions.

Older adults

Antibody responses may be lower and wane sooner with age. A non-reactive result in an older adult should not be read as evidence that vaccination failed, and a reactive one should not be read as licence to skip recommended doses.

People with diabetes

Diabetes does not interfere with the antibody assay itself. If fasting tests are being drawn in the same sitting and you take insulin or other glucose-lowering medicines, ask your prescriber how to time your dose and carry a fast-acting carbohydrate in case of hypoglycaemia.

Chronic kidney disease, dialysis and heart failure

The blood draw itself is straightforward, though venous access may be more difficult, and dialysis fistula arms are not used for routine sampling. People on dialysis or with immune suppression may mount weaker antibody responses. Anyone under a medical fluid restriction should not increase fluid intake for a blood test.

Immunocompromised patients

This is the group in which antibody testing is most often clinically considered, and also the group in which it is hardest to interpret. Decisions on additional vaccine doses or preventive therapy rest with the treating specialist.

COVID-19 antibody testing in the Indian context

• Regulatory framework: COVID-19 diagnostic kits used in India require validation and approval under the applicable regulatory pathway, with ICMR and CDSCO having issued kit evaluation and advisory frameworks during the pandemic. Laboratories should be able to tell you the kit and platform used. Guideline positions have changed repeatedly across the pandemic, confirm the current national advisory with your laboratory or clinician.
• Serosurveys: ICMR conducted national serological surveys using IgG assays to estimate population exposure. Those surveys illustrate the appropriate use of IgG testing: population-level estimates, not individual immunity certificates.
• Local terminology: patients commonly ask for a "COVID antibody test", "COVID blood test" or "immunity test". Collection centres may list it as SARS-CoV-2 IgG (CLIA), anti-spike IgG, or COVID ELISA. Confirm which antigen the test targets before booking.
• Common misuse seen in practice: self-referred antibody tests before travel, before or instead of a vaccine dose, or during an acute febrile illness. None of these is an appropriate indication, and an antibody test is not accepted in place of RT-PCR where a molecular test is required.
• Data protection: health records and test bookings are personal data. Under the Digital Personal Data Protection Act 2023, laboratories collecting your details should tell you how the data will be used and obtain consent.
• Vaccination context: India ran one of the largest COVID-19 vaccination programmes globally, including inactivated whole-virion and protein/viral-vector platforms. This matters because inactivated vaccines can produce anti-nucleocapsid antibodies, which weakens the usual assumption that anti-N positivity means natural infection.

Cost and insurance in India

COVID-19 IgG antibody testing is generally an inexpensive to moderately priced blood test in India, and prices have fallen substantially since the pandemic peak. Charges differ widely between cities, between government and private laboratories, and between platforms. Ask for the current rate at the point of booking, since any figure quoted online is indicative only and changes without notice.

Factors that influence the price:

• Platform used, rapid cassette versus ELISA versus automated CLIA/ECLIA
• Whether the test is qualitative (reactive/non-reactive) or quantitative with numeric units
• Antigen target and whether spike and nucleocapsid are tested separately
• Whether IgG is billed alone or within a panel
• Home collection charges, urgent processing, and referral to an outside laboratory
• City, sector (government, trust, corporate) and accreditation status of the laboratory
• Government-notified price caps, where these apply

Insurance: outpatient diagnostic tests are often not covered unless your policy includes an OPD or diagnostic benefit. Coverage is more likely when the test is part of an admitted episode of care ordered by the treating doctor. Tests done on your own initiative, without a prescription, are usually not reimbursed. Check with your insurer or the hospital's insurance desk before testing.

Myths and facts

Frequently asked questions

Can a COVID-19 IgG antibody test tell me if I am infectious?

No. The IgG antibody test detects your immune response, not the virus. A person can be infectious with an undetectable IgG, and someone with a strongly reactive IgG may carry no virus at all. Infectiousness questions need a swab-based test, interpreted alongside your symptoms and exposure history by your doctor.

How soon after infection or vaccination does IgG become detectable?

IgG generally becomes detectable days to a couple of weeks after symptom onset or after a vaccine dose, but the timing varies considerably between individuals and between assays. Testing too early commonly produces a non-reactive result. Your doctor will advise the appropriate interval based on your history and the assay used.

Which is more accurate, antibody testing or RT-PCR?

The comparison does not hold, because the two tests answer different questions. RT-PCR detects viral RNA and is the reference test for current infection. Antibody testing looks for evidence of a past immune response. Neither can substitute for the other, and accuracy depends on why the test was ordered.

What is the difference between TrueNat and standard RT-PCR?

TrueNat is a portable, chip-based real-time PCR platform originally developed for tuberculosis and adapted for SARS-CoV-2. TrueNat allows molecular testing at smaller or remote facilities with faster local turnaround. It remains a PCR method and shares PCR's limitations, including sensitivity to sampling quality and the need for protocol-defined confirmatory steps.

Should I test antibodies before deciding on a booster dose?

Routine antibody testing is not recommended for booster decisions. No threshold defines who needs a dose, and a reactive result does not mean a dose is unnecessary. Discuss vaccination with your doctor, who will consider your age, medical conditions, immune status and current national recommendations.

Why does my report mention spike or nucleocapsid antibodies?

Those are the viral proteins the assay targets. Anti-spike IgG can follow infection or most vaccines, so it cannot distinguish them. Anti-nucleocapsid IgG has been used to suggest past natural infection, though inactivated whole-virus vaccines can also produce it. Ask your laboratory which antigen was tested before interpreting the result.

Is fasting needed for the COVID-19 antibody test?

Fasting is generally not required for SARS-CoV-2 IgG testing. If the same blood draw includes a lipid profile or fasting glucose, the fasting requirement for those tests applies. Instructions differ between laboratories, so follow the written instruction given by your collection centre, which takes precedence.

Can I use a home rapid antibody kit instead of a laboratory test?

Home rapid antibody cassettes vary considerably in performance and are easily misread. Laboratory platforms such as CLIA and ELISA are generally more reliable and report against a defined cut-off. In either case, the result needs interpretation in clinical context, so share any home result with your doctor rather than acting on it alone.

My antibody test is non-reactive after vaccination. Did the vaccine fail?

Not necessarily. The assay may target an antigen your vaccine does not contain, antibodies may have waned, or your response may simply sit below the cut-off. Protection also depends on T-cell and memory B-cell immunity, which this test does not measure. Raise the result with your doctor before drawing conclusions.

Sources

• World Health Organization, guidance and scientific briefs on SARS-CoV-2 antibody (serological) testing and diagnostic testing for SARS-CoV-2
• Indian Council of Medical Research, advisories on COVID-19 testing strategy, antibody test kit evaluation, and national serosurvey reports
• Central Drugs Standard Control Organisation, regulatory framework for in-vitro diagnostic kit approval in India
• US Centers for Disease Control and Prevention, interim guidelines for COVID-19 antibody testing, including statements on antibody results and immunity
• US Food and Drug Administration, safety communication on the limitations of SARS-CoV-2 antibody testing for assessing immunity
• Digital Personal Data Protection Act, 2023 (India), handling of personal health data